The estimated Net Worth of Margaret Mc Loughlin is at least $1.1 Million dollars as of 8 October 2021. Margaret Loughlin owns over 1,000 units of Cortexyme Inc stock worth over $1,950 and over the last 5 years he sold CRTX stock worth over $30,333. In addition, he makes $1,072,160 as Independent Director at Cortexyme Inc.
Margaret has made over 4 trades of the Cortexyme Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 1,000 units of CRTX stock worth $17,000 on 8 October 2021.
The largest trade he's ever made was exercising 6,000 units of Cortexyme Inc stock on 16 August 2021 worth over $102,000. On average, Margaret trades about 1,013 units every 110 days since 2019. As of 8 October 2021 he still owns at least 1,000 units of Cortexyme Inc stock.
You can see the complete history of Margaret Loughlin stock trades at the bottom of the page.
Dr. Margaret A. Mcloughlin Ph.D. serves as Independent Director of the Company. From January 2014 to April 2019, Dr. McLoughlin served as an Executive Director in World Wide Business Development, at Pfizer Inc. focusing on venture investments, and from June 2018 to April 2019, she was a Partner in Pfizer Ventures, a venture capital arm of Pfizer Inc. focused on companies working in areas aligned with the future directions of Pfizer Inc. Dr. McLoughlin served as a director on the board of directors of 4D Molecular Therapeutics, System1 Biosciences and Adapsyn Biosciences. Dr. McLoughlin joined Pfizer Inc. in 2001 and prior to focusing on venture investments, had roles of increasing responsibility within Worldwide Business Development where she led transactions with multiple biotech companies, academic institutions and other large pharma companies. Prior to working at Pfizer Inc., Dr. McLoughlin served as a Director in Yale’s Office of Cooperative Research for two years. Dr. McLoughlin served in various positions at Mallinckrodt Medical from 1992 to 1999, holding positions in Discovery Research, followed by Technology Planning. Dr. McLoughlin holds a B.S. in Chemistry from the University of California, Irvine and a Ph.D. in Chemistry from the University of California, Santa Barbara. McLoughlin is qualified to serve as a director because of her extensive experience in the biotechnology industry and her service on a number of boards, which provides an important perspective on operations and corporate governance matters, as well as her education in biotechnology.
As the Independent Director of Cortexyme Inc, the total compensation of Margaret Mcloughlin at Cortexyme Inc is $1,072,160. There are 1 executives at Cortexyme Inc getting paid more, with Michael Detke having the highest compensation of $1,100,170.
Margaret Mcloughlin is 57, he's been the Independent Director of Cortexyme Inc since 2015. There are 4 older and 14 younger executives at Cortexyme Inc. The oldest executive at Cortexyme Inc is Una Ryan, 78, who is the Lead Independent Director.
Margaret's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: